B Sangro Gómez-Acebo

Summary

Affiliation: University of Navarra
Country: Spain

Publications

  1. doi request reprint Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation
    Bruno Sangro
    Liver Unit, Clinica Universidad de Navarra and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBEREHD, Pamplona, Spain
    Hepatology 54:868-78. 2011
  2. doi request reprint A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
    Bruno Sangro
    Liver Unit and HPB Oncology, Clinica Universidad de Navarra, Pamplona, Spain
    J Hepatol 59:81-8. 2013
  3. doi request reprint Radioembolization for hepatocellular carcinoma
    Bruno Sangro
    Liver Unit, Clinica Universidad de Navarra, Pamplona, Spain
    J Hepatol 56:464-73. 2012
  4. ncbi request reprint Gene therapy for liver cancer: clinical experience and future prospects
    Bruno Sangro
    Clinica Universitaria de Navarra, Liver Unit, Avenida Pio XII 36, 31008 Pamplona, Spain
    Curr Opin Mol Ther 12:561-9. 2010
  5. doi request reprint Liver disease induced by radioembolization of liver tumors: description and possible risk factors
    Bruno Sangro
    Liver Unit, Department of Internal Medicine, University Clinic and CIBERHD, Pamplona, Spain
    Cancer 112:1538-46. 2008
  6. ncbi request reprint [Treatment of hepatocarcinoma]
    B Sangro Gómez-Acebo
    Unidad de Hepatologia, Clinica Universitaria de Navarra, Avda Pio XII, 36, 31008 Pamplona, Navarra
    Gastroenterol Hepatol 25:36-42. 2002
  7. ncbi request reprint Future therapies for hepatocellular carcinoma
    Bruno Sangro
    The Liver Unit, Clinica Universitaria de Navarra, Fundacion para la Investigacion Medica Aplicada, University of Navarra, Pamplona, Spain
    Eur J Gastroenterol Hepatol 17:515-21. 2005
  8. ncbi request reprint Gene therapy of cancer based on interleukin 12
    Bruno Sangro
    Liver Unit, Clinica Universitaria de Navarra, and the Division of Hepatology and Gene Therapy, Centro de Investigación Médica Aplicada, Pamplona, Spain
    Curr Gene Ther 5:573-81. 2005
  9. ncbi request reprint Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma
    Bruno Sangro
    Liver Unit, Department of Internal Medicine, Clinica Universitaria de Navarra, Pamplona, Spain
    Int J Radiat Oncol Biol Phys 66:792-800. 2006
  10. doi request reprint Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres
    Bruno Sangro
    Liver Unit, Centro de InvestigaciónBiomédica en Red de Enfermedades Hepáticas y Digestivas, Pamplona, Spain
    Dig Dis 27:164-9. 2009

Collaborators

Detail Information

Publications55

  1. doi request reprint Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation
    Bruno Sangro
    Liver Unit, Clinica Universidad de Navarra and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas CIBEREHD, Pamplona, Spain
    Hepatology 54:868-78. 2011
    ..All-cause mortality was 0.6% and 6.8% at 30 and 90 days, respectively. Conclusion: This analysis provides robust evidence of the survival achieved with radioembolization, including those with advanced disease and few treatment options...
  2. doi request reprint A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
    Bruno Sangro
    Liver Unit and HPB Oncology, Clinica Universidad de Navarra, Pamplona, Spain
    J Hepatol 59:81-8. 2013
    ....
  3. doi request reprint Radioembolization for hepatocellular carcinoma
    Bruno Sangro
    Liver Unit, Clinica Universidad de Navarra, Pamplona, Spain
    J Hepatol 56:464-73. 2012
    ..With a number of clinical trials underway, the available evidence shows that it adds a significant value to the therapeutic weaponry against HCC of tertiary care centers dealing with this major cancer problem...
  4. ncbi request reprint Gene therapy for liver cancer: clinical experience and future prospects
    Bruno Sangro
    Clinica Universitaria de Navarra, Liver Unit, Avenida Pio XII 36, 31008 Pamplona, Spain
    Curr Opin Mol Ther 12:561-9. 2010
    ..The development of new gene therapy vectors with improved characteristics will increase the probability of success of gene therapy for the treatment of liver cancer...
  5. doi request reprint Liver disease induced by radioembolization of liver tumors: description and possible risk factors
    Bruno Sangro
    Liver Unit, Department of Internal Medicine, University Clinic and CIBERHD, Pamplona, Spain
    Cancer 112:1538-46. 2008
    ..To the authors' knowledge, liver damage after liver radioembolization with yttrium90-labeled microspheres has never been studied specifically...
  6. ncbi request reprint [Treatment of hepatocarcinoma]
    B Sangro Gómez-Acebo
    Unidad de Hepatologia, Clinica Universitaria de Navarra, Avda Pio XII, 36, 31008 Pamplona, Navarra
    Gastroenterol Hepatol 25:36-42. 2002
  7. ncbi request reprint Future therapies for hepatocellular carcinoma
    Bruno Sangro
    The Liver Unit, Clinica Universitaria de Navarra, Fundacion para la Investigacion Medica Aplicada, University of Navarra, Pamplona, Spain
    Eur J Gastroenterol Hepatol 17:515-21. 2005
    ..Increasing efforts in basic and clinical development of these approaches will hopefully result in more efficient therapies against HCC...
  8. ncbi request reprint Gene therapy of cancer based on interleukin 12
    Bruno Sangro
    Liver Unit, Clinica Universitaria de Navarra, and the Division of Hepatology and Gene Therapy, Centro de Investigación Médica Aplicada, Pamplona, Spain
    Curr Gene Ther 5:573-81. 2005
    ..New vectors that might achieve regulated, long-term production of this cytokine might have better results and merit clinical testing...
  9. ncbi request reprint Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma
    Bruno Sangro
    Liver Unit, Department of Internal Medicine, Clinica Universitaria de Navarra, Pamplona, Spain
    Int J Radiat Oncol Biol Phys 66:792-800. 2006
    ..To investigate the antitumor effect of resin microspheres loaded with 90-yttrium against hepatocellular carcinoma and their safety in the setting of liver cirrhosis...
  10. doi request reprint Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres
    Bruno Sangro
    Liver Unit, Centro de InvestigaciónBiomédica en Red de Enfermedades Hepáticas y Digestivas, Pamplona, Spain
    Dig Dis 27:164-9. 2009
    ....
  11. ncbi request reprint [Hepatocarcinoma treatment]
    B Sangro Gómez-Acebo
    Unidad de Hepatologia, Clinica Universitaria de Navarra, Pamplona
    Rev Clin Esp 204:218-20. 2004
  12. ncbi request reprint Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors
    Bruno Sangro
    Liver Unit, Division of Gene Therapy, Department of Internal Medicine, Clinica Universitaria, University of Navarre, Ap 4209 Pamplona 31080, Spain
    J Clin Oncol 22:1389-97. 2004
    ..To evaluate the feasibility and safety of intratumoral injection of an adenoviral vector encoding human interleukin-12 genes (Ad.IL-12) and secondarily, its biologic effect for the treatment of advanced digestive tumors...
  13. doi request reprint A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma
    B Sangro
    Liver Unit, Clinica Universitaria, Pamplona, Spain
    Cancer Gene Ther 17:837-43. 2010
    ..One of them achieved a sustained stabilization and survived for 26 months. In conclusion, Ad.TK can be safely administered by intratumoral injection to patients with HCC up to 2 × 10¹² vp per patient...
  14. ncbi request reprint Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma
    Bruno Sangro
    Liver Unit, Department of Internal Medicine, Clinica Universitaria, Pamplona, Spain
    Oncology 62:293-8. 2002
    ..To analyze the results of an intra-arterially delivered combination chemotherapy in a group of patients with regionally advanced hepatocellular carcinoma (HCC)...
  15. doi request reprint Transarterial therapies for hepatocellular carcinoma
    Bruno Sangro
    Liver Unit, Clinica Universitaria de Navarra, Pamplona, Spain
    Expert Opin Pharmacother 12:1057-73. 2011
    ..However, the scientific evidence supporting the use of transarterial therapy is heterogeneous and certainly weak for several subgroups. New developments have emerged in the last decade...
  16. ncbi request reprint Gene therapy of neoplastic liver diseases
    Bruno Sangro
    Division of Gene Therapy, Department of Internal Medicine, Clinica Universitaria de Navarra, AP 4209, 31080, Pamplona, Spain
    Int J Biochem Cell Biol 35:135-48. 2003
    ..Pre-clinical evidence and early clinical trials strongly suggest that there is a place for gene therapy of liver malignancies...
  17. doi request reprint Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma
    Mercedes Inarrairaegui
    Liver Unit, Department of Internal Medicine, Clinica Universitaria de Navarrra, Pamplona, Spain
    Int J Radiat Oncol Biol Phys 77:1441-8. 2010
    ..To analyze which patient-, tumor-, and treatment-related factors may influence outcome after (90)Y radioembolization ((90)Y-RE) for hepatocellular carcinoma (HCC)...
  18. doi request reprint Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors
    Jose I Bilbao
    Department of Radiology, Clinica Universitaria de Navarra, Universidad de Navarra, Avenida de Pio XII n masculine 36, Pamplona 31008, Spain
    Cardiovasc Intervent Radiol 33:523-31. 2010
    ..Redistribution of flow in L-RS is feasible and enables a safe and effective delivery of (90)Y resin microspheres that are able to be distributed via intrahepatic collaterals and access the microvasculature of L-RS...
  19. ncbi request reprint Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients
    Ivan Penuelas
    Department of Nuclear Medicine, Clinica Universitaria de Navarro, Pamplona, Spain
    Gastroenterology 128:1787-95. 2005
    ....
  20. doi request reprint Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis
    Mercedes Inarrairaegui
    Liver Unit, Clinica Universitaria de Navarra, Pamplona, Spain
    J Vasc Interv Radiol 21:1205-12. 2010
    ..This retrospective analysis was undertaken to assess the safety and clinical benefits of radioembolization with (90)Y resin microspheres in HCC with branch or main PVT...
  21. doi request reprint Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages
    Delia D'Avola
    Liver Unit, Clinica Universitaria de Navarra, Pamplona, Spain
    Ann Surg Oncol 18:1964-71. 2011
    ..We evaluated the effect of compliance with BCLC treatment allocation on the prognosis of patients with hepatocellular carcinoma (HCC)...
  22. ncbi request reprint A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma
    Delia D'Avola
    Liver Unit, Clinica Universitaria, Pamplona, Spain
    Hepatogastroenterology 56:1683-8. 2009
    ..to determine the impact of Y90-Radioembolization on survival when used as a first-line treatment for unresectable HCC...
  23. doi request reprint Liver transplantation in patients with hepatocellular carcinoma across Milan criteria
    J Ignacio Herrero
    Liver Unit, Clinica Universitaria de Navarra, Pamplona Navarra, Spain
    Liver Transpl 14:272-8. 2008
    ..In conclusion, following CUN criteria could increase the number of HCC patients who could benefit from LT, without worsening the results. Because of the short number of patients in this series, these data need external validation...
  24. ncbi request reprint Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas
    Guillermo Mazzolini
    Division of Hepatology and Gene Therapy, Department of Radiology, Clinica Universitaria School of Medicine, University of Navarra, C Irunlarrea, S N, 31008 Pamplona, Spain
    J Clin Oncol 23:999-1010. 2005
    ..Secondarily, we have evaluated biologic effects and antitumoral activity...
  25. doi request reprint Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
    Carlos Alfaro
    Gene Therapy and Hepatology Unit, Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain
    J Immunol 187:6130-42. 2011
    ..This combinatorial immunotherapy strategy is safe and feasible, and its immunobiological effects suggest potential activity in patients with minimal residual disease. A randomized trial exploring this hypothesis is currently ongoing...
  26. ncbi request reprint Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8
    Esperanza Feijoo
    Division of Hepatology and Gene Therapy, Clinica Universitaria School of Medicine, Foundation for Applied Medical Research, Universidad de Navarra, Pamplona, Spain
    Int J Cancer 116:275-81. 2005
    ..Impairment of DC migration toward lymphoid tissue could be involved in cancer immune evasion...
  27. doi request reprint Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report
    J Ignacio Herrero
    Liver Unit, Clinica Universitaria de Navarra, Pamplona, Spain
    Clin Transplant 23:532-6. 2009
    ..5 months). The difference in survival between both groups was significant (p = 0.002). In conclusion, a close surveillance protocol for the diagnosis of malignancy could be life-saving in liver transplant recipients...
  28. doi request reprint Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation
    Jose I Bilbao
    Department of Radiology, Clinica Universitaria de Navarra, Universidad de Navarra, Avenida de Pio XII, 36, 31008 Pamplona, Spain
    J Vasc Interv Radiol 19:1625-38. 2008
    ..To perform a study in a porcine model comparing four different spherical embolic particles in terms of postembolization patency, deformation, and potential for recanalization, with a focus on a relatively new agent--HepaSphere...
  29. ncbi request reprint Gene therapy of liver diseases
    Jesus Prieto
    Department of Internal Medicine, Clinica Universitaria de Navarra, Avda Pio XII 36, 31008 Pamplona, Spain
    Expert Opin Biol Ther 4:1073-91. 2004
    ..Recent progress in vector technology and imaging techniques, allowing in vivo assessment of gene expression, will facilitate the development of clinical applications of gene therapy...
  30. ncbi request reprint Biologic therapy of liver tumors
    Jesus Prieto
    Division of Hepatology and Gene Therapy, Fundación para la Investigación Médica Aplicada FIMA, University of Navarra, Avenida Pio XII s n, 31080 Pamplona, Spain
    Surg Clin North Am 84:673-96. 2004
    ..Combination of biological modifiers, gene therapy, and cell therapy will hopefully provide efficient means to combat inoperable neoplasms in a not-very-distant future...
  31. ncbi request reprint Gene therapy of hepatocellular carcinoma and gastrointestinal tumors
    Bruno Sangro
    Gene Therapy Unit, Department of Internal Medicine, Clinica Universitaria, Universidad de Navarra, Pamplona, Spain
    Ann N Y Acad Sci 963:6-12. 2002
    ..In summary, a variety of gene therapy strategies have been effective against animal models of gastrointestinal tumors. Clinical trials should determine whether human patients can be treated safely and effectively by such strategies...
  32. ncbi request reprint De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival
    J Ignacio Herrero
    Liver Unit, Clí nica Universitaria, Av Pio XII, 36 31008 Pamplona, Spain
    Liver Transpl 11:89-97. 2005
    ..This increased risk is due to the development of noncutaneous neoplasia. Older age, alcoholism, and smoking increase the risk of de novo noncutaneous neoplasia...
  33. doi request reprint Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal
    J Ignacio Herrero
    Liver Unit, University Clinic of Navarra, Pamplona, Spain
    Liver Transpl 17:402-8. 2011
    ..In conclusion, smoking withdrawal after liver transplantation may have a protective effect against the development of neoplasia...
  34. ncbi request reprint Herpes zoster after liver transplantation: incidence, risk factors, and complications
    J Ignacio Herrero
    Liver Unit, Clinica Universitaria de Navarra, Pamplona, Spain
    Liver Transpl 10:1140-3. 2004
    ..In conclusion, herpes zoster is a relatively common complication after liver transplantation. It is related to immunosuppressive therapy. Postherpetic neuralgia develops in one third of patients with posttransplant herpes zoster...
  35. ncbi request reprint Nonmelanoma skin cancer after liver transplantation. Study of risk factors
    J Ignacio Herrero
    Liver Unit, Clinica Universitaria, Pamplona, Spain
    Liver Transpl 11:1100-6. 2005
    ..In conclusion, risk of posttransplant NMSC may be estimated combining skin type and an easy estimation of total sun burden. No individual immunosuppression regimen seems to be related to a higher risk of NMSC...
  36. ncbi request reprint Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer
    Lin Wang
    Faculty of Medicine, University of Navarra, Pamplona, Spain
    Gastroenterology 126:278-89. 2004
    ..Gene therapy of liver diseases would benefit from systems allowing prolonged, regulable, and tissue-specific transgene expression. We attempted to produce a vector fulfilling these requirements...
  37. ncbi request reprint Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion
    Maite Herraiz
    Division of Hepatology and Gene Therapy, University of Navarra, Medical School Pamplona, 31008 Pamplona, Spain
    Hum Gene Ther 14:463-72. 2003
    ..These data are relevant for the design of clinical trials using adenoviral vectors encoding HSV-tk...
  38. doi request reprint A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma
    Paul C Schröder
    Division of Hepatology and Gene Therapy, Proteomics, Genomics and Bioinformatics Unit, Center for Applied Medical Research, University of Navarra, Pamplona, Spain
    Funct Integr Genomics 11:419-29. 2011
    ..In addition to revealing the impairment of central metabolic pathways for liver homeostasis, further studies may probe the potential value of the reported genes for the early detection of HCC...
  39. ncbi request reprint Positron emission tomography and gene therapy: basic concepts and experimental approaches for in vivo gene expression imaging
    Ivan Penuelas
    Department of Nuclear Medicine, Clinica Universitaria de Navarra, Pamplona, Spain
    Mol Imaging Biol 6:225-38. 2004
    ....
  40. doi request reprint Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy
    Maria J Perugorria
    Division of Hepatology and Gene Therapy, CIMA and CIBERehd, University Clinic, University of Navarra, Pamplona, Spain
    Cancer Res 69:1358-67. 2009
    ..In conclusion, WT1 is expressed in a substantial proportion of HCC contributing to tumor progression and resistance to chemotherapy, suggesting that WT1 may be an important target for HCC treatment...
  41. ncbi request reprint Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy
    J Ignacio Herrero
    Department of Surgery, Clinica Universitaria, Pamplona, Spain
    Am J Transplant 3:1407-12. 2003
    ..In conclusion, older liver transplant recipients have a significantly lower survival than younger patients. Malignancy is responsible for this decreased survival...
  42. ncbi request reprint [Diagnosis of small hepatocellular carcinoma]
    Mercedes Inarrairaegui
    Unidad de Hepatologia, Departamento de Medicina Interna, Clinica Universitaria de Navarra, Pamplona, Navarra, Espana
    Gastroenterol Hepatol 30:498-505. 2007
    ....
  43. doi request reprint Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo
    Natalia Suarez
    Biochemistry Department, Clinica Universidad de Navarra, Pamplona, Spain
    Int J Cancer 129:374-86. 2011
    ..Taken together, these experiments indicate that tremelimumab therapy may benefit from previous or concomitant T(reg) depletion...
  44. ncbi request reprint The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis
    Raquel Rios
    Liver Unit, Clinica Universitaria de Navarra, Pamplona, Spain
    Am J Gastroenterol 100:1311-6. 2005
    ..The main goal of this study is to clarify the role of TPO in the pathogenesis of thrombocytopenia in cirrhosis...
  45. ncbi request reprint Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial
    Mariam Conchillo
    Department of Medicine and Liver Unit, Clinica Universitaria, Medical School and Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    J Hepatol 43:630-6. 2005
    ..Insulin-like growth factor I (IGF-I) is an anabolic hormone synthesized in the liver whose levels decrease sharply in liver cirrhosis...
  46. ncbi request reprint Gene therapy of liver cancer
    Ruben Hernandez-Alcoceba
    Division of Gene Therapy and Hepatology, Foundation for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    Ann Hepatol 6:5-14. 2007
    ..Some of these strategies have reached early clinical development with diverse little success...
  47. pmc Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings
    Jose I Bilbao
    Department of Radiology, Clinica Universitaria de Navarra, Universidad de Navarra, Avenida de Pio XII, 36, Pamplona, 31008, Spain
    Cardiovasc Intervent Radiol 32:727-36. 2009
    ..There was no evidence of either a prolonged inflammatory reaction or fibrosis in the liver parenchyma following recannalization...
  48. ncbi request reprint A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis
    Juan Felipe Lucena
    Clinica Universitaria and Medical School, University of Navarra, Medicine and Liver Unit, Pamplona, Navarra, Spain
    Gastroenterology 124:1037-42. 2003
    ....
  49. doi request reprint Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection
    Jose Ignacio Riezu-Boj
    Gene Therapy and Hepatology Area, Center for Applied Medical Research CIMA, University of Navarra, Pamplona, Spain
    J Hepatol 54:422-31. 2011
    ..The mechanisms by which Foxp3+ T regulatory cells (Treg) accumulate in HCV infected livers are not known. Here, we studied the role of chemokines CCL17 and CCL22 in this process...
  50. doi request reprint Spontaneous regression of hepatocellular carcinoma: a systematic review
    Susana Oquiñena
    Department of Gastroenterology, Hospital Virgen del Camino, Pamplona, Spain
    Eur J Gastroenterol Hepatol 21:254-7. 2009
    ..To estimate the actual frequency of spontaneous regression of hepatocellular carcinoma...
  51. ncbi request reprint Gastroduodenal injury after radioembolization of hepatic tumors
    Cristina Carretero
    Department of Gastroenterology, Liver Unit, University Clinic of Navarra, Navarra, Spain
    Am J Gastroenterol 102:1216-20. 2007
    ..Radioembolization is a new tool for the treatment of hepatic tumors that consists in the injection of biocompatible microspheres carrying radioisotopes into the hepatic artery or its branches...
  52. doi request reprint Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?
    Jose L Perez-Gracia
    Centro de Investigación Médica Aplicada y Clinica Universitaria Universidad de Navarra, Avenida de Pio XII 55, 31008 Pamplona, Spain
    Immunotherapy 1:845-53. 2009
    ..Such 'short-cut' combination immunotherapy trials can bring much needed efficacy earlier to the bedside...
  53. ncbi request reprint Pneumatosis coli due to pharmacological constipation
    Cesar Prieto
    Digestive Diseases Division, University of Navarra, Pamplona, Spain
    Gastrointest Endosc 65:710-1. 2007
  54. pmc Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib
    Bruno Sangro
    Liver Unit, Clinica Universidad de Navarra
    Rare Tumors 4:e34. 2012
    ..Sorafenib therapy resulted in durable stabilization with progressive calcification of liver tumors and minor but stable response of lung lesions...
  55. doi request reprint Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations
    Bruno Sangro
    Clinica Universitaria de Navarra and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas, Pamplona, Spain
    Am J Clin Oncol 34:422-31. 2011
    ....